FCF Biotech Venture Capital Monitor – USA 01/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 01/2022”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of January 2022, we identify the following current VC trends in the US-Biotech sector:

  • Total financing volume for biotech companies in the US since the beginning of the year amounts to USD 5,324m
  • The top 5 deals already surpassed USD 100m each in the first month of the year
  • The largest deal volume amounted to USD 3,000m for Altos Labs
  • Surveyor Capital dominates the top 5 investors by deal size (USD 61m), followed by Foresite Capital Management (USD 60m) and General Catalyst (USD 46m)
  • Central nervous system is the indication with the highest investment activity at the beginning of the year

To access the full report, please click here.

By Dr. Mathias Schott and Sebastian Sommer

Share
[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]